Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 1, 2008, Pages 99-104

  Mlambo, C K ^a   Warren, R M ^b   Poswa, X ^c   Victor, T C ^b   Duse, A G ^a   Marais, Else ^a,d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d NONE   (South Africa)

Author keywords

MDR TB; Mycobacterium tuberculosis; XDR TB

Indexed keywords

AMINOGLYCOSIDE; ETHIONAMIDE; KANAMYCIN; OFLOXACIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DISEASE TRANSMISSION; GENETIC VARIABILITY; GEOGRAPHY; HUMAN; ISOLATION PROCEDURE; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM ANALYSIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; HUMANS; KANAMYCIN; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PHENOTYPE; SOUTH AFRICA; SPUTUM;

EID: 38349002419     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. World Health Organization, International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Geneva, Switzerland: WHO, 2004. http://www.who.int/tb/publications/who_htm_tb_2004_343/ en/ Accessed August 2007.
2. Holtz T H, Lancaster J, Laserson K F, et al. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; 10: 649-655.
3. Bifani P J, Mathema B, Liu Z, et al. Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology. JAMA 1999; 282: 2321-2327.
4. van Rie A, Warren R M, Beyers N, et al. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling 'strain W' among noninstitutionalized, human immunodeficiency virus-seronegative patients. J Infect Dis 1999; 180: 1608-1615.
5. Toungoussova O S, Mariandyshev A, Bjune G, et al. Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison in Russia: predominance of the W-Beijing clone family. Clin Infect Dis 2003; 37: 665-672.
6. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR 2006; 55: 301-305.
7. World Health Organization. WHO media report. WHO Global Task Force outlines measures to combat XDR-TB worldwide. Geneva, Switzerland: WHO, 2006. http://www.who.int/mediacentre/news/notes/2006/np29/en/index.html Accessed August 2007.
8. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
9. Mathema B, Kurepina N E, Bifani P J, et al. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 2006; 19: 658-685.
10. Masjedi M R, Farnia P, Sorooch S, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43: 841-847.
11. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914.
12. Brudey K, Driscoll J R, Rigouts L, et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006; 6: 23.
13. Grimaldo E R, Tupasi T E, Rivera A B, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.
14. Centers for Disease Control and Prevention. European concerted action on new generation genetic markers and techniques for the epidemiology and control of tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 2006; 12: 736-743.
15. Marais B J, Victor T C, Hesseling A C, et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J Clin Microbiol 2006; 44: 3539-3543.
16. Richardson M, van Lill S W, van der Spuy G D, et al. Historic and recent events contribute to the disease dynamics of Beijing-like Mycobacterium tuberculosis isolates in a high incidence region. Int J Tuberc Lung Dis 2002; 6: 1001-1011.
17. Small P M, Hopewell P C, Singh S P, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
18. van Rie A, Enarson D. XDR tuberculosis: an indicator of public-health negligence. Lancet 2006; 368: 1554-1556.
19. Weyer K, Groenewald P, Zwarenstein M, et al. Tuberculosis drug resistance in the Western Cape. S Afr Med J 1995; 85: 499-504.
20. Shisana O, Rehle T, Simbayi L C, et al. South African National HIV Prevalence, HIV Incidence, Behaviour and Communication Survey, 2005. Cape Town, South Africa: Human Sciences Research Council Press, 2005.